The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Biotechnology
Jiangsu Sihuan Price, Forecast, Insider, Ratings, Fundamentals & Signals
4.80% CNY2.40
America/New_York / 6 mai 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 470.94 mill |
| EPS: | -0.0600 |
| P/E: | -40.00 |
| Earnings Date: | May 21, 2024 |
| SharesOutstanding: | 1 029.56 mill |
| Avg Daily Volume: | 35.63 mill |
| RATING 2024-05-06 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -40.00 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.37x |
| Company: PE -40.00 | industry: PE 29.29 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY0.0828 (-96.55%) CNY-2.32 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
CNY 2.22 - 2.48 ( +/- 5.49%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY2.40 (4.80% ) |
| Volume | 39.37 mill |
| Avg. Vol. | 35.63 mill |
| % of Avg. Vol | 110.48 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 000518.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
000518.SZ
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.